A reference set of health utilities for long-term survivors of prostate cancer: Population-based data from Ontario, Canada - Abstract

PURPOSE: To measure quality of life (QOL) and utilities for prostate cancer (PC) patients and determine their predictors.

METHODS: A population-based, community-dwelling, geographically diverse sample of long-term PC survivors in Ontario, Canada, was identified from the Ontario Cancer Registry and contacted through their referring physician. Consenting patients completed questionnaires by mail: Health Utilities Index (HUI 2/3), Patient Oriented Prostate Utility Scale PORPUS-U (utility), PORPUS-P (health profile), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and Prostate Cancer Index (PCI). Clinical data were obtained from chart reviews. Regression models determined the effects of a series of variables on QOL and utility.

RESULTS: We received questionnaires and reviewed charts for 585 patients (mean age 72.6, 2-13 years postdiagnosis). Mean utility scores were as follows: PORPUS-U = 0.92, HUI2 = 0.85, and HUI3 = 0.78. Mean health profile scores were as follows: PORPUS-P = 71.7, PCI sexual, urinary, and bowel function = 23.7, 79.1, and 84.6, respectively (0 = worst, 100 = best), and FACT-P = 125.1 (0 = worst, 156 = best). In multiple regression analyses, comorbidity and PCI urinary, sexual, and bowel function were significant predictors of other QOL measures. With all variables, 32-50 % of the variance in utilities was explained.

CONCLUSIONS: Many variables affect global QOL of PC survivors; only prostate symptoms and comorbidity have independent effects. Our model allows estimation of the effects of multiple factors on utilities. These utilities for long-term outcomes of PC and its treatment are valuable for decision/cost-effectiveness models of PC treatment.

Written by:
Krahn MD, Bremner KE, Alibhai SM, Ni A, Tomlinson G, Laporte A, Naglie G.   Are you the author?
Department of Medicine, University of Toronto, Toronto, Canada.

Reference: Qual Life Res. 2013 Apr 6. Epub ahead of print.
doi: 10.1007/s11136-013-0401-1

 
PubMed Abstract
PMID: 23564620

UroToday.com Prostate Cancer Section